Growth & Partnerships

Embla Medical reported Q4 2025 sales of USD 257 million, up 14% in USD terms and 10% in local currency, with organic growth of 7% versus 5% in Q4 2024. FY 2025 organic sales growth was 6%. EBITDA margin for the quarter fell to 19% from 21% due to FX, tariffs, and initiatives aimed at long‑term profitability in Patient Care. Net profit rose 33% to USD 25 million, giving a net profit margin of 10% of sales. For 2026, the company forecasts 5‑8% organic sales growth and an EBITDA margin of 20‑22%; its NIBD/EBITDA before special items ratio stood at 2.4× at Q4 2025, within target. Concurrently, Embla opened a prosthetic clinic in Kyiv and partnered with the Government of Iceland to launch the “Iceland Supports Mobility in Ukraine” initiative.